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Abstract
Introduction
The amyloid precursor protein (APP) is mainly known for being the precursor of the ß-amyloid peptide, which accumulates in 
plaques found in the brain of Alzheimer’s disease patients. Expression in different tissues and the degree of sequence identity among 
mammals indicate an essential and non-tissue specific physiological function. APP is anchored to the membrane and displays a single 
C-terminal intracellular domain and a longer N-terminal extracellular domain. The basic biochemical properties and the scattered 
data on research, not related to production of beta-amyloid peptide, suggest that the protein and the molecules resulting from APP 
proteolytic cleavage may act as adhesion factors, enzymes, hormones/neurotransmitters and/or protease inhibitors. APP deserves to 
be known for its quite notable properties and its physiological role(s).
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The number of papers related to amyloid precursor protein (APP) as of September 2014 is 30,075. Of those, papers in this Century 
are 24,390 (81% of the total), indicating that APP is one of the most studied proteins. Information is useful but excess of data may 
be counterproductive by the risk of losing the perspective to fully apprehend APP biological clues. A key issue in understanding 
APP biological relevance is to focus on its physiological role(s). As every other protein, APP may have different roles; a main one 
and other(s) possibly less relevant. This certainty drives scientific research. Due to enormous interest related to accumulation of a 
degradation peptide, beta-amyloid (Aß) peptide, in the brain of Alzheimer’s disease (AD) patients, APP research is biased towards 
the central nervous system (CNS) and mainly driven by its relationship with the amyloid-hypothesis of AD. The protein is widely 
expressed and is highly conserved among species; therefore its physiological function must be essential and non-tissue specific, i.e. 
not necessarily centered on the nervous system.
In this perspective paper the focus is placed on aspects apparently attracting less interest in the field, namely the possibility of i) a 
relevant role of carbohydrates in APP function, ii) differential APP glycosylation in AD, iii) APP acting as adhesion molecule, iv) 
APP having enzyme activity, v) APP proteolytic cleavage providing polypeptides with hormone/neurotransmitter/growth factor 
potential, and vi) soluble APP acting as protease inhibitor in the CNS.
Keywords: Alzheimer’s disease; Adhesion; Autocrine; CD26; CVAP; Differentiation cluster; Enzyme; Hormone; Lymphocyte; 
Neurotransmitter; Paracrine; Protease; Protease inhibitor; Protease nexin 2; protease nexin II
A conserved and widely expressed protein
APP acquired its present name after the discovery of its fundamental relationship with AD. In fact, one of the hallmarks of the 
disease is the presence of plaques formed by aggregates of a hydrophobic peptide of the protein in patient’s brain. This cleavage 
peptide corresponds to amino acids 671-712 of APP and is known as ß-amyloid or Aß (1-40 or 1-42). In the NIH internet page 
“Genetics home reference” one may obtain information about the protein such as the official name, “amyloid beta (A4) precursor 
protein”, or the alternative names for the APP gene or the gene product: “A4_HUMAN, AAA, ABPP, AD1, amyloid beta-protein 
precursor, amyloid precursor protein, APPI, cerebral vascular amyloid peptide, CVAP, PN2, PN-II, protease nexin 2, protease nexin-
II”. Very relevant for the present article is the information about its physiological function. In fact, in the same web page one may 
read: “Little is known about the function of amyloid precursor protein. Researchers speculate that it may bind to other proteins on the 
surface of cells or help cells attach to one another. Studies suggest that in the brain, it helps direct the movement (migration) of nerve 
cells (neurons) during early development”. In this paper we will rescue important data of APP structure and putative function, and 
propose ways to advance in the understanding of the physiological APP role.
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It is difficult to find proteins whose primary structure (amino acid sequence) is so conserved among mammals. There is a 96.6% 
identity between APP sequence in mouse and human. A similarly high mouse-human degree of homology is found for a relevant 
protein in muscle function, creatine kinase M-type. The mouse-human identity is 92% for one of the main G-protein-coupled 
receptors, the alpha-1A adrenergic receptor (92 %, same length, 466 amino acids). The mouse-human degree of identity in the 
sequence of adenosine deaminase, which has been studied in our laboratory for years and whose congenital defect causes severe 
combined immunodeficiency, is 83%. In addition, the deduced protein sequence derived from the cDNA sequence is 770 amino 
acids long in many mammals. Moreover, the APP protein is widely expressed in different tissues. These simple and easily obtainable 
pieces of information are extremely relevant and point to a fundamental physiological role.
The primary structure deduced from the mammalian APP gene is quite unique1. For many proteins an extra amino acid does not 
result in any evident gain/loss of function2. If the protein has catalytic activity, the enzymatic and regulatory properties would not 
change much upon addition or removal of a couple of amino acids at the beginning (N-terminus) or at the end (C-terminus) of 
its sequence. The equal length of the predicted APP-sequence in many mammals unequivocally indicates that an extra amino acid 
has not been evolutionary successful, suggesting that length modification would result in a marked loss of function.
Despite the genome and proteome are quite similar among mammals, equal predicted length [1,2] in the primary structure of 
proteins is more the exception than the rule. There are important proteins with equal length in human and mouse: glucokinase 
(465) or caveolin-1 (178). In contrast ubiquitin D has 165 amino acids in human and 162 in mouse, insulin precursor has 110 
amino acids in human whereas the mouse has two non-allelic genes, one coding for an insulin precursor of 110 and for another 
of 108 amino acids. Metabotropic glutamate receptor is five amino acids longer than the human counterpart (1194 in human 
and 1199 in mouse). Dopamine D4 receptor, a G-protein-coupled receptor, is much longer in human (467) than in mouse (397). 
Whereas adenosine deaminase is longer in men (363) than in mice (352), a 363 amino-acid-long protein is also found in a variety 
of mammals: Pongo pygmaeus abelii (Sumatran orangutan), Callithrix jacchus (White-tufted-ear marmoset), Pan troglodytes 
(Chimpanzee), Saimiri boliviensis boliviensis (Bolivian squirrel monkey), Macaca mulatta (Rhesus macaque), Macaca fascicularis 
(Crab-eating macaque) (Cynomolgus monkey), Nomascus leucogenys (Northern white-cheeked gibbon) (Hylobates leucogenys) 
and Mustela putorius furo (European domestic ferret). However, identity in these sequences of equal length is quite poor (50%). 
In summary, APP is quite unique in having (among mammals) a totally conserved length and a very high degree of inter-species 
sequence identity.
Equal length and similar sequence for different species
Focus on the biochemistry of APP
Alternative splicing of the APP mRNA leads to three forms of 695, 751 and 770 amino acids [2-6]. A fourth form of 563 amino 
acids that does not contain the Aß peptide sequence was also reported. Expressed in cell models, the 695 and 751 forms are further 
sialic-acid glycosylated and phosphorylated to add 20 kDa to the apparent molecular mass of the protein [7]. Despite alteration 
of APP glycosylation has been reported in AD (see [8] for a review), the consequences of APP biochemical processing in both 
healthy humans and AD patients are unknown. Alterations in carbohydrate content of a heavily glycosylated protein, alpha1-
antitrypsin, in cancer patients were investigated early in time [9]. Since then, the methods for determination of carbohydrates in 
human samples have advanced considerably, and ultimate mass-spectrometry technology makes possible fast determination of 
the slightest variation in protein glycosylation [10]. To look for APP glycosylation in different tissues and in AD could give light 
to the contribution of carbohydrates to the function of APP.
Proteolysis may be regarded as a non-physiologically relevant  step in protein degradation. Nevertheless, there are many examples 
about the relevance of proteolytic events such as the cleavage of pro-insulin to give the physiologically active hormone, or the 
activation of a digestive pro-enzyme to give the active enzyme (e.g. chymotrypsinogen converted into chymotrypsin). Importantly, 
even in such cases the research has focused on the active protein but not on the other proteolytic fragments. One would consider that 
short peptide fragments are not neutral but interact with intracellular or extracellular components. Do these natural degradation 
fragments have physiological functions? Considering APP, one can suggest that this is the case. In fact, if a protein has equal 
length in mammals and has a very well controlled proteolytic cleavage (Figure 1), the products of this degradation are predicted 
to be unique and with a physiological role. APP may be processed by the amyloidogenic pathway, which results in Aß peptide (a 
40-42 amino-acid-long peptide), or by the non-amyloidogenic pathway. The amyloidogenic route has been considered aberrant 
as it produces a peptide that self-aggregates and that is enriched in the “amyloid” plaques found in the brain of AD patients. The 
amyloid hypothesis of AD, i.e. the assumption that Aß peptide production is key for AD pathology, has not provided the expected 
results in terms of adequate and effective medications for patients. All of the anti-Aß peptide approaches, whose description is 
out of the scope of the present article, have been unsuccessful [11]. But what it is relevant is that the amyloidogenic pathway is not 
just restricted to the brain of AD patients; the pathway is also active in the healthy human brain. Again, the question that arises is 
similar to that above indicated: is there any physiological role for amyloid processing and for Aß peptide? It is very likely. Is there 
a role for the APP fragment remaining attached to the cell membrane? It is also likely. And is there a role for the secreted APP? It 
is likely as well.
1. This section refers to protein sequence length predicted from the APP gene. Splice variants leading to different protein isoforms have been reported (see below). 
2. Surely, addition or removal of amino acids in the middle of the sequence may have important structural/functional consequences.
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Potential roles for APP
This section takes advantage of basic data on APP to highlight aspects that are usually forgotten and/or less commented. Pulse and 
chase experiments with radiolabelled sulfur were instrumental to know how APP is synthesized and processed. Synthesis of APP 
is followed by glycosylation, maturation, and rapid proteolysis to provide two stable fragments: a high molecular mass protein 
that is secreted and a low molecular mass form that contains the Aß peptide sequence and remains attached to the cell membrane 
[7,12,13]. Taking the basic structure of APP and its cell surface expression, a few are the physiological roles biting the bait. APP may 
be an adhesion molecule, something that to our knowledge has not been considered much despite well-substantiated evidence by 
Breen et al. (1991) and Coulson et al. (1997). Adhesion molecules have in common with APP the relatively long extracellular and the 
single trans-membrane domain [14,15]. They are also type-1 membrane proteins, i.e. they have the N-terminus at the extracellular 
side. Type-1 membrane proteins may also be differentiation clusters (CDs) in lymphocytes. Is APP expressed in immune cells? Yes, 
as summarized by Bush et al., in 1993: “APP exists in the blood as full-length, potentially amyloidogenic forms in platelets, and as an 
attenuated species in plasma and T-lymphocytes” [16].
APP-independent amyloid deposits may be found in human pancreas. Islet amyloid polypeptide (iAPP) is considered a pancreatic 
hormone and comes from the degradation of a 90 amino acid precursor protein (the length varies among mammals). The predicted 
amino acid sequence identity for this hormone is less than that displayed by APP (versus human: 89% in cat, 84% in rat and mouse, 
and 78% in guinea pig) [17]. By analogy, peptides coming from APP processing may be messenger  molecules (hormones or 
neuromodulators/neurotransmitters). As we understand it, hormonal signaling can be autocrine, paracrine and endocrine (Figure 
2). Due to both the widespread distribution and the relatively small amount in plasma, soluble APP may not act as an endocrine 
hormone. However, autocrine and paracrine actions cannot be ruled out. 
Figure 1: Amyloidogenic and non-amyloidogenic APP-processing pathways.
Aß: ß-amyloid peptide. AICD: Short peptides from the intracellular domain of APP.
α, ß and γ indicate processing by, respectively, α, ß and γ secretases. C83 and C99 are C-terminal fragments of respectively, 83 and 99 kDa. sAPP is soluble APP. 
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Also noteworthy is the identification of a cell-secreted protease inhibitor, protease nexin-II (PN-II) as identical to the deduced 
amino-terminal sequence of APP [30]. The so-called secreted form of APP is in fact produced by proteolysis of the membrane-
attached precursor. Due to enrichment in brain and to potent inhibition of blood coagulation factor XIa, PN-II, i.e. soluble APP, 
was proposed as a locally-acting cerebral anticoagulant [31]. The Kunitz-type protease inhibitor domain in APP [5] indeed inhibits 
coagulation factor XIa, thus contributing to prevent carotid and cerebral artery thrombosis [32,33]. This protease-inhibitor potential 
should be further explored in different tissues (also in CNS). Interestingly, soluble APP inhibits and binds tightly to active trypsin 
released from cancer cells [34]. This finding reinforces the protease inhibitor role of the soluble form of the protein and opens the 
possibility to consider soluble APP as target in malignancies. PN-II has been also reported to interact and mediate the cellular 
binding of the epidermal growth factor binding protein, another serine protease [35-38]. 
Reports on Aß peptide function are biased towards understanding mechanisms of neurodegeneration. It should be however noted 
that Aß peptide seems to be protective in oxidative stress conditions. A controversy concerning whether Aß peptide is indeed toxic 
or part of a cellular defense mechanism exists in the AD field. The finding of intracellular Aß peptide accumulation in the brain 
of healthy humans is also consistent with a “normal” physiological role of the so-called amyloidogenic APP processing [18,19]. 
Quite remarkably, accumulation is not restricted to older individuals but occurs across all ages, i.e. also in infants [19]. Of note, 
Aß peptide would require a carrier system for the uptake of the peptide that is, in principle, released to the extracellular milieu. 
APP processing in the endoplasmic reticulum with direct production of intracellular Aß peptide cannot however be ignored. Some 
controversial results on the in vivo studies of Aß effects were provided by Joseph et al., in 2001; in the authors’ own words toxicity by 
the amyloid peptide is not proven: “ … putative Aß toxicity… which still has not been convincingly demonstrated in vivo” [20]. Could 
the Aß peptide act as an autocrine or paracrine hormone? Using recently developed label-free technologies it would be interesting 
to investigate if APP-derived soluble peptides can signal in neuronal primary cultures. 
CD26 is a differentiation cluster that has been well characterized in different tissues. CD26 interacts with other cell surface proteins, 
for instance with chemokine receptors [21] and plays a role in HIV-infection [22] CD26 was studied in intestinal mucosa as 
enzyme, dipeptidyl peptidase IV, and in lymphocytes as co-stimulatory molecule in T-cell activation [23-26]. Could APP have an 
enzymatic activity and be a co-stimulatory molecule in the immune system? For comparison purposes, it is important to note that 
soluble CD26 may be released from proteolytic cleavage of membrane-bound CD26 [27]. In other words, circulating dipeptidyl 
peptidase IV (soluble CD26) results from shedding from cell membranes. The role of soluble CD26 is not totally known but the 
enzymatic activity contributes to regulate the plasma concentration of chemokines [28,29]. To our knowledge soluble CD26 does 
not have a specific cell surface receptor and therefore an endocrine/autocrine/paracrine function cannot be at present endowed. 
Figure 2: Scheme of autocrine, paracrine and endocrine hormonal action.
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APP synthesis and proteolytic processing already occur in embryonic neural differentiation [39-41]. Furthermore, soluble APP may 
promote neurite outgrowth among other trophic actions [42]. The potential autocrine/paracrine role would fit with neurotrophin 
p75 being the receptor that mediates the neurotrophic actions of soluble APP [43]. Interestingly, a tight binding of PN-II to the 
gamma subunit of nerve growth factor allows this factor to interact with cells [44]. Soluble APP also interacts with transforming 
growth factor (TFG) beta 2 [45]. This interaction points to APP being involved in one of the main pathways regulating differentiation 
and growth in many tissues. Actually an important function in neural development has been assigned to APP (See [46], for review). 
In Drosophila melanogaster, the homologous gene to mammalian APP predicts a protein of 886 amino acids and belongs to the vnd 
locus, which is essential in flies for embryonic nervous system development [47]. To our knowledge no systematic approach to find 
soluble APP binding proteins in human fluids or tissues has been attempted. In this regard, the study performed by Golabek et al., 
(1995) to detect Aß-peptide-interacting partners may be an example to follow [48].
Conclusion
The length of the predicted APP sequence, 770 amino acids, is equal in many mammals and the overlap of the mouse and human 
sequences is quite unique. This equal length and almost equal sequence indicates that the proteolytic processing is important 
for physiological APP function. The biochemical data and scattered studies suggest diverse roles for APP and for the molecules 
resulting from its proteolytic degradation. APP and derivatives may be from adhesion molecules to hormones/neurotransmitters. 
Glycosylation is one important feature of APP that may be useful to ascertain its physiological role. The possibility of APP 
glycosylation as a blood biomarker in AD deserves attention.
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